RenovoRx, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
RenovoRx is a clinical-stage biopharmaceutical company developing local solid-tumor therapies using its RenovoTAMP platform. Its lead candidate, RenovoGem, combines intra-arterial gemcitabine with the RenovoCath delivery device. The unaudited quarter ended March 31, 2022; comparative results are for the three months ended March 31, 2021. The company had no product sales or approved drug/device combination products.
Financial highlights
Unless stated otherwise, amounts are in millions of dollars; the financial statements present amounts in thousands.
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.289 | $0.635 |
| General and administrative expense | $1.716 | $0.418 |
| Total operating expenses | $3.005 | $1.053 |
| Net loss | $3.003 | $1.148 |
| Basic and diluted loss per share | $0.33 | $0.51 |
| Net cash used in operating activities | $2.097 | $0.992 |
| Cash and cash equivalents | $13.121 at Mar. 31, 2022 | $15.192 at Dec. 31, 2021 |
| Working capital | $12.5 | Not stated for comparable date |
| Total liabilities | $1.406 at Mar. 31, 2022 | $0.938 at Dec. 31, 2021 |
Gross margin and operating margin are not meaningful because the company had no revenue. Management reported no contractual obligations or other commitments as of the report date and no off-balance-sheet arrangements. No debt balance was reported at quarter-end; convertible notes had converted in connection with the August 2021 IPO, and the PPP loan was forgiven in 2021.
Material changes versus the prior comparable period
- Operating expenses increased 185% year over year; net loss increased 162% to $3.003 million.
- R&D expense rose 103%, mainly due to Phase 3 clinical development, clinical consulting, staffing, preclinical work, regulatory and quality consulting, and establishing a secondary RenovoCath manufacturer.
- G&A expense rose 311%, reflecting higher staffing, legal and post-IPO professional costs, and directors’ and officers’ insurance.
- Operating cash use more than doubled to $2.097 million. Cash declined $2.071 million from year-end 2021, partly offset by $0.026 million of option-exercise proceeds.
- Loss per share narrowed despite the higher total loss, as weighted-average shares increased to 8.99 million from 2.24 million following the IPO and share conversions.
Outlook, commentary, and risks
- Management believes March 31 cash is sufficient to fund operations, investing, and financing needs for at least 12 months from issuance of the statements, assuming programs advance as planned. The company expects continued losses, increasing expenses, and no product revenue for several years, if ever; additional financing may be needed, with no committed funding source.
- The Phase 3 TIGeR-PaC trial had reached approximately 50% of target enrollment as of March 15, 2022. The planned interim analysis is tied to 65 deaths; management expected it between Q4 2022 and Q1 2023, while noting timing is difficult to predict.
- Management planned to discuss the design of a Phase 2 extrahepatic cholangiocarcinoma trial with FDA in Q2 or Q3 2022 and, if FDA did not object to the protocol, anticipated starting the study in the second half of 2022.
- COVID-19 had affected trial recruitment and patient visits and could cause further clinical, vendor, or supply delays. The company reported no material supply-chain disruption to date. It also cited inflation, workforce competition, and the Russia-Ukraine conflict as potential sources of economic and operating risk.
- RenovoCath was obtained from a single source, and the company relies substantially on third parties for clinical trials and manufacturing. Clinical, regulatory, manufacturing, reimbursement, competition, and financing risks remain significant.
- Disclosure controls were deemed ineffective due to a previously identified material weakness in financial reporting controls, including insufficient accounting expertise and staffing, inadequate written procedures and review controls, and insufficient segregation of duties. Management was implementing remediation measures and intended to complete them during 2022; effectiveness had not yet been established.
- The company reported no material legal proceedings. Its Los Altos headquarters lease was due to expire May 31, 2022.
Important facts for investors to verify
- Progress toward Phase 3 enrollment and the timing, design, and results of the interim analysis, including any trial protocol changes.
- Whether the planned FDA discussion and potential launch of the eCCA Phase 2 trial occurred as anticipated.
- Cash burn, actual runway, and timing and terms of any additional financing; equity or debt funding could dilute holders or impose restrictions.
- Progress in qualifying a secondary RenovoCath manufacturer and the supply arrangements for device and drug materials.
- Remediation of the material weakness and whether disclosure controls and internal financial reporting controls become effective.
- Potential dilution: 2,786,995 warrants were outstanding at March 31, 2022, exercisable at $10.80 per share; reported common shares were 9,029,305 at March 31 and 9,066,863 at May 10, 2022.